Skip to content
Press Releases
Filter Releases
 
Press Releases
Jul 18, 2017
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its second quarter 2017 financial results after the close of market on Monday, July 31, 2017. Following the announcement, Veracyte's management will host a live conference call and webcast at ...
PDF
Jun 27, 2017
SOUTH SAN FRANCISCO, Calif., June 27, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today that results of a study supporting the early development of the Envisia Genomic Classifier have been published online in the Annals of the American Thoracic Society.  The genomic test, introduced commercially in October 2016, is used to improve ...
PDF
Jun 26, 2017
SOUTH SAN FRANCISCO, Calif., June 26, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today that it has been awarded a 2017 Top Workplaces honor by the Bay Area News Group. This marks the fourth consecutive year that Veracyte has received this prestigious award, which is based solely on the results of an annual survey of Bay Area-compa...
PDF
Jun 1, 2017
SOUTH SAN FRANCISCO, Calif., June 1, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William Blair 2017 Growth Stock Conference on Thursday, June 15, 2017 at 8:00 a.m. CT in Chicago, IL. The live webcast from the William Blair conference and...
PDF
May 23, 2017
SOUTH SAN FRANCISCO, Calif., May 23, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced today that pivotal clinical validation data demonstrating the performance of its Envisia Genomic Classifier were presente...
PDF
May 18, 2017
SOUTH SAN FRANCISCO, Calif., May 18, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that Anthem, Inc., an independent Blues plan and one of the nation's largest health benefits companies, has issued...
PDF
May 11, 2017
SOUTH SAN FRANCISCO, Calif., May 11, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that data demonstrating the cost-effectiveness of the Percepta Bronchial Genomic Classifier were published for the first ...
PDF
May 10, 2017
SOUTH SAN FRANCISCO, Calif., May 10, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that data from multiple studies supporting use of the company's genomic classifiers to improve the diagnosis of lun...
PDF
May 8, 2017
SOUTH SAN FRANCISCO, Calif., May 8, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced new data from two studies demonstrating that use of the Afirma Gene Expression Classifier (GEC) significantly reduce...
PDF
May 4, 2017
SOUTH SAN FRANCISCO, Calif., May 4, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced data from a pivotal clinical validation study of its Afirma Genomic Sequencing Classifier (GSC). The data suggest th...
PDF
Page:
...
Next Last